Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 49 clinical trials
Featured trial
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

This is an open-label, monotherapy study of INCB054828 in subjects with myeloid/lymphoid neoplasms with FGFR1 rearrangement.  Subjects will receive a once daily (QD) dose of INCB054828

FGFR1
lymphoid malignancy
myeloid neoplasm
  • 182 views
  • 10 May, 2022
  • 35 locations
A Phase I, Open-label, Parallel Group Study to Investigate Olaparib Safety and Tolerability, Efficacy and Pharmacokinetics in Paediatric Patients With Solid Tumours

A study to find out whether olaparib is safe and well tolerated when administered to children and adolescents with solid tumours.

  • 33 views
  • 20 Sep, 2022
  • 20 locations
  • 0 views
  • 04 Jun, 2021
  • 1 location
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of SHR2554 in participants with relapsed or refractory mature lymphoid neoplasms in part I, and the the efficacy in PTCL patients

  • 7 views
  • 13 May, 2022
  • 1 location
The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma

(IV) infusion to patients with lymphoid malignancies.

  • 7 views
  • 15 Mar, 2022
  • 5 locations
First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION)

Part 1 will be a dose escalation study of IV ICT01 (a monoclonal antibody targeting BTN3A) as monotherapy in patients with advanced solid or hematologic tumors, followed by a cohort examining the combination of ICT01 plus pembrolizumab (Keytruda). Part 2 will be a cohort expansion into 2-3 solid tumor indications …

follicular lymphoma
leukemia
advanced cancer
measurable disease
hematologic malignancy
  • 1 views
  • 26 Mar, 2022
  • 6 locations
Futibatinib in Patients With Specific FGFR Aberrations

-esophageal junction (GEJ) cancer harboring FGFR2 amplification; and patients with myeloid or lymphoid neoplasms with FGFR1 rearrangements.

  • 1 views
  • 23 Jul, 2022
  • 57 locations
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients

The basic premise of this research proposal is to determine whether there is any significant association between germline polymorphisms and cancers of colon, bladder, breast, testicular, prostate, ovaries, kidney, lung, lymphoid organs, and head and neck. This is an exploratory study designed to generate hypotheses for further research.

primary tumor
BRCA1
cancer
cytokines
BRCA2
  • 14 views
  • 24 Apr, 2022
  • 1 location
A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL

The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]) and optimal dosing schedule(s) of JNJ-75348780 in participants with relapsed/ refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) in Part A and to further characterize the safety at the …

follicular lymphoma
mantle cell lymphoma
b-cell lymphoma
chronic lymphocytic leukemia
beta human chorionic gonadotrophin
  • 14 views
  • 17 Sep, 2022
  • 31 locations
Duvelisib in Combination With CC-486 in Lymphoid Malignancy

The purpose of the study is to find a safe dose and to evaluate the safety and tolerability of the drug CC-486, in combination with duvelisib.

  • 0 views
  • 10 Oct, 2021
  • 1 location